Affomix has proprietary technology for rapid, automated, high-throughput selection of human monoclonal antibodies (mAbs). Their mission is to commercialize proprietary mAbs, mAb microarrays and mAb libraries for research, drug discovery, diagnostic and therapeutic applications, with a particular focus on the use of their mAbs for sensitive and accurate measurement of very large numbers of proteins in biological samples.
Funding Rounds (1) - $7MUpdate
Current Team (1)Update
|Dec 18, 2009||VentureDeal - Affomix Corporation raises 7000000 in venture round|
688 East Main Street
Branford, CT 06405